Status:

RECRUITING

ATA-200 Dose-escalation Gene Therapy Trial in Patients With LGMDR5

Lead Sponsor:

Atamyo Therapeutics

Conditions:

LGMD2C

Eligibility:

All Genders

6-13 years

Phase:

PHASE1

PHASE2

Brief Summary

The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5)....

Detailed Description

This is a multicenter Phase 1b assessing the safety and tolerability of 2 doses of ATA-200 for the treatment of LGMDR5. The dose escalation phase will enroll ambulant patients with LGMDR5. Two dose c...

Eligibility Criteria

Inclusion

  • Confirmed diagnosis of LGMDR5 before age of 10, based on clinical presentation and genotyping
  • Ambulant male or female patients aged 6 to less than 12 years of age at screening
  • Able to perform the 10-meter walk test (10MWT) in less than 15 sec and to rise from chair with or without arm support

Exclusion

  • Detectable neutralizing antibodies against AAV8
  • Cardiomyopathy with left ventricular ejection fraction (LVEF) \< 50%
  • Respiratory assistance
  • Concomitant medical condition that might interfere with LGMDR5 evolution
  • Acute illness within 4 weeks of anticipated IMP administration
  • Current participation in another clinical trial with investigational medicinal product
  • Previous participation in gene and cell therapy trials
  • Any condition that would contraindicate immunosuppressant treatment
  • Presence of any permanent items (e.g., metal braces) precluding undergoing MRI
  • Any vaccination 1 month prior to planned IMP administration
  • Serology consistent with HIV exposure or active hepatitis B or C infection
  • Grade 2 or higher lab abnormalities for liver function tests, creatinine, hemogram and coagulation

Key Trial Info

Start Date :

February 15 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

January 31 2031

Estimated Enrollment :

6 Patients enrolled

Trial Details

Trial ID

NCT05973630

Start Date

February 15 2025

End Date

January 31 2031

Last Update

October 6 2025

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Child Health Research Institute

Gainesville, Florida, United States, 32610

2

Hopital Trousseau

Paris, France

3

Ospedale Maggiore Policlinico

Milan, Italy